EQS News: Marinomed Biotech AG: Launch of the new allergen-blocking Carragelose product in Austria and market launch in Mexico

adminn

6 months ago

EQS News: Marinomed Biotech AG: Launch of the new allergen-blocking Carragelose product in Austria and market launch in Mexico

EQS News: Marinomed Biotech AG / Key word(s): Market launch Marinomed Biotech AG: Launch of the new allergen-blocking Carragelose product in Austria and market launch in Mexico 04/11/2024 / 07:45 CET/CEST The issuer is responsible for the content of the announcement / Editor responsible. ═════════════════════════════════════════ ═════════ ═════════════════════════════════════════ ═════════ ═════════════════════════════════════════ ═════════ ══════════════ Marinomed Biotech AG: Launch of the new allergen-blocking Carragelose product in Austria and market launch in Mexico • New, allergen-blocking nasal spray for the treatment of hay fever in Austria complements the existing OTC product portfolio • Partner M8 Pharmaceuticals Launches Carragelose Nasal Spray to Treat Viral Respiratory Infections in Mexico • Additional Value and Sales Potential for Carragelose Business Korneuburg, Austria, April 11, 2024 – Marinomed Biotech AG (VSE:MARI) today announces the expansion of its Carragelose portfolio with new product launches in Austria and Mexico, paving the way for the development of new indications and key markets. Marinomed’s Austrian sales partner Sigmapharm recently launched a new nasal spray under the brand name COLDAMARIS Allergy to treat the symptoms of hay fever caused by grass pollen. The launch comes in time for the peak of this year’s allergy season. Carragelose nasal spray is used to both prevent and relieve allergy symptoms such as dry, runny or stuffy nose, itching and sneezing. The market launch of this allergen-blocking nasal spray is an important milestone in the expansion of the established Carragelose portfolio from virus-blocking to allergic indications, thereby enabling year-round sales potential beyond the typical cold season. Following successful approval by Marinomed’s sales partner M8 Pharmaceuticals (a subsidiary of Acino) last summer, a Carragelose nasal spray is now available in Mexico under the brand name Barlo®. Since Mexico is the second largest pharmaceutical market in Latin America, this market launch has significant sales potential. “With the market launch of our first Carragelose product in the field of immunology and the product launch in Mexico, the second largest pharmaceutical market in Latin America, we have reached important milestones in the continuous expansion of our Carragelose portfolio. We are well on our way to closing further geographical gaps in Europe, the Middle East and Latin America with new and existing partners and targeting new indications. This makes us less dependent on the cold season, enables year-round sales and gives rise to new growth opportunities,” comments Andreas Grassauer, CEO of Marinomed. “In addition to these developments, the market launch of Carragelose eye drops and the submission of approval with Procter & Gamble in the USA are also progressing well.” About Carragelose®: Carragelose® is a sulfated polymer from red algae with a unique, broad spectrum of virus and allergen blocking effects. It is known to be a tolerated, effective and safe agent for the prevention and treatment of viral respiratory diseases. Several clinical and preclinical studies have shown that Carragelose® forms a protective layer on the mucous membrane that prevents viruses from infecting cells. Laboratory studies and clinical data have confirmed that Carragelose® can also prevent the transmission of SARS-CoV-2.^(1)(1),(2)(2) Marinomed holds the patent rights to Carragelose® and has approved Carragelose® for distribution in Europe, North America, Australia and other countries in Asia and Latin America. Marinomed’s Carragelose® portfolio of nasal sprays and throat products can be found at (3) https://www.carragelose.com/en/portfolio/launched-productsthe scientific publications on Carragelose® at (4) https://www.marinomed.com/de/publikationen/wissenschaftliche-publikationen.

About Marinomed Biotech AG Marinomed Biotech AG is an Austrian, science-based biotechnology company with a growing development pipeline and globally marketed therapeutics. The company develops patent-protected, innovative products in the therapeutic areas of immunology and virology based on its Marinosolv® platform and the virus-blocking effect of Carragelose®. The Marinosolv® technology increases the solubility and bioavailability of poorly soluble active ingredients and is used to develop new therapeutics for indications in the area of autoreactive immune diseases. The Virology segment includes Carragelose®-based over-the-counter products for the prevention and treatment of viral upper respiratory tract infections, partnered in more than 40 countries. The company is based in Korneuburg, Austria and is listed on the Prime Market of the Vienna Stock Exchange (VSE:MARI). Further information: (5) https://www.marinomed.com.

Inquiry note Marinomed Biotech AG International media inquiries PR & IR: Lucia Ziegler Metrum Communications: Eva Ruppnig T: +43 2262 90300 158 T: +43 664 4065744 E-mail: (6)pr@marinomed.com E-mail: (8)marinomed@metrum.at E-mail: (7)ir@marinomed.com Disclaimer This press release contains forward-looking statements that are based on current views, expectations and forecasts of the management of Marinomed Biotech AG about future events. These forward-looking statements are subject to risks, uncertainties and assumptions that could cause actual results, performance or events to differ materially from those described or otherwise expressed or implied by such statements. The current views, expectations and forecasts of the management of Marinomed Biotech AG are influenced by the context of such statements or words as “anticipate”, “believe”, “estimate”, “expect”, “intend”, “plan”, “project” and Recognize “target”. Forward-looking statements speak only as of the date on which they are made. Marinomed Biotech AG undertakes no obligation to update, revise or revise any forward-looking statements contained in this press release, whether as a result of new information, future developments or otherwise. Marinomed, Marinosolv® and Carragelose® are brands of Marinomed AG. The brands are the property of Marinomed Biotech AG or are licensed out to partners in selected countries. (9)^(1) (10)https://www.dovepress.com/efficacy-of-a-nasal-spray-containing-iota-carrageenan-in-the-postexpos-peer-reviewed-fulltext-article- IJGM (11)^(2) (12)https://www.marinomed.com/de/news/marinomed-biotech-ag-informs-about-positive-clinical-results-for-iota-carrageenan-nasal-spray-for -covid-19-praevention-1 ═════════════════════════════════════ ═════ ═════════════════════════════════════════ ═════════ ═════════════════════════════════════════ ═════════ ══════════════════════ 04/11/2024 CET/CEST Publication of a corporate news/financial announcement, transmitted by EQS Group AG. www.eqs.com